Company
Tempus Ai
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
6
510(k), De Novo and PMA
Device trials
2
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
TEM
Nasdaq · Tempus AI, Inc.
Public float
$11.0B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$1.27B
Fiscal year ending Dec 31, 2025
Net income
-$245M
Fiscal year ending Dec 31, 2025
R&D spending
$173M
Fiscal year ending Dec 31, 2025
Cash
$590M
As of Sep 30, 2026
Long-term debt
$176M
As of Sep 30, 2026
Shares outstanding
Not reported
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | – | $726M |
| 2024 | $382M | – | – | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
- Tempus ECG-MR510(k)
K254297 · Decided Sep 25, 2026 · 268 days after receipt
Device type: Atrial Fibrillation Risk Prediction Machine Learning-Based Notification Software (SBQ) · Cardiology
- Tempus ECG-PH510(k)
K253699 · Decided Aug 21, 2026 · 270 days after receipt
Device type: Pulmonary Hypertension Machine Learning-Based Notification Software (SAT) · Cardiology
- xR IVD510(k)
K241868 · Decided Sep 19, 2025 · 449 days after receipt
Device type: Next Generation Sequencing Based Tumor Profiling Test (PZM) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary HypertensionPivotal-lookingRecruiting
NCT06911632 · 900 participants (planned) · Start Jul 23, 2025 · Primary completion May 2028
Device: ECG-based AI Device - Results Returned to Investigator; ECG-based AI Device - Results Not Returned to Investigator · For: Pulmonary Hypertension; Interstitial Lung Disease (ILD)
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 41 sites in all
NCT05442203 · 1,000 participants (planned) · Start Sep 7, 2022 · Primary completion Jul 2025
Device: Zio Patch Monitor; Echocardiogram · For: Atrial Fibrillation; Structural Heart Disease
Sites: Grand Rapids, Michigan; Cincinnati, Ohio; Danville, Pennsylvania
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.